Georgetown University Neurology Clinical Research (GUNCR)

• HEALEY ALS Platform Trial
  • Study Coordinator: Eli Wolfgang (ew746@georgetown.edu (new window))

• Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
  • Study Coordinator: Eli Wolfgang (ew746@georgetown.edu (new window))

• Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures (TALSLB)
  • Study Coordinator: Christopher Gough (ccg46@georgetown.edu (new window))

• (MOVR) neuroMuscular ObserVational Research data hub
  • Study Coordinator: Eli Wolfgang (ew746@georgetown.edu (new window))

• Human Epilepsy Project 3 (HEP3)
  • Study Coordinator: Emma Waldon (etw19@georgetown.edu (new window))

• Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System. (CORE-VNS)
  • Study Coordinator: Emma Waldon (etw19@georgetown.edu (new window))

• A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine (ASCEND)
  • Study Coordinator: Chris Gough (ccg46@georgetown.edu (new window))

• An Open-Label, Multiple-Dose Evaluation of the Efficacy and Safety of AXS-07 (meloxicam and rizatriptan) for the Acute Treatment of Migraine in Adults with a Prior Inadequate Response to an Oral CGRP Inhibitor (Axsome AXS-07-304)
  • Study Coordinator: Chris Gough (ccg46@georgetown.edu (new window))

• Preventive Treatment of migraine: Outcomes for Patients in real-world Healthcare systems (TRIUMPH)
  • Study Coordinator: Chris Gough (ccg46@georgetown.edu (new window))

• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O’HAND)
  • Study Coordinator: Sayeed Shahriar (ss4407@georgetown.edu (new window))

• A Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Ocrelizumab In Adult Participants With Primary Progressive Multiple Sclerosis (GN41791 / FENtrepid)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu (new window))

• Study of Diroximel Fumarate in the Real-World Setting (EXPERIENCE)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu (new window))

• Study To Evaluate The Efficacy And Safety Of Fenebrutinib Compared With Teriflunomide In Relapsing Multiple Sclerosis (RMS) (FENhance) (GN42272)
  • Study Coordinator: Sayeed Shahriar (ss4407@georgetown.edu (new window))

• Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (TREAT-MS)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu (new window))

• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu (new window))

• A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder (ECU-NMO-303)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu (new window))

• CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Study Coordinator: Sayeed Shahriar (ss4407@georgetown.edu (new window))

• A Study to Investigate the Efficacy and Safety of NT 201 (Botulinum Toxin) Compared With Placebo for the Treatment of Adult Participants With Essential Tremor in the Arm
  • Study Coordinator: Luke Lovelace (ll928@georgetown.edu (new window))

• Product Surveillance Registry (PSR)
  • Study Coordinator: David Pisfil (ddp39@georgetown.edu (new window))

• PROSEEK: A Phase 2 Study In Early Parkinson’s Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 (CLR_18_06 / PROSEEK)
  • Study Coordinator: Luke Lovelace (ll928@georgetown.edu (new window))

• Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson’s Disease
  • Study Coordinator: Luke Lovelace (ll928@georgetown.edu (new window))

• Acute Stroke Program of Interventions Addressing Racial and Ethnic Disparities (ASPIRE)
  • Study Coordinator: Emma Waldon (etw19@georgetown.edu (new window))

• A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (M19-148 / EAISE)
  • Study Coordinator: Emma Waldon (etw19@georgetown.edu (new window))

• AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke (ARCADIA)

Study Coordinator: Emma Waldon (etw19@georgetown.edu (new window))